ASCO 2020: "Unprecedented" disease-free survival demonstrated for Tagrisso

Detailed results from the Phase III ADAURA trial released for the first time showed that Tagrisso (osimertinib) demonstrated a statistically-significant and clinically-meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent, Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) announced late yesterday.

Results will be presented during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Sunday (May 31). AstraZeneca’s shares were up 2.6% at 8,922 pence in late morning trading today.

In the primary endpoint of DFS in patients with Stage II and IIIA disease, adjuvant treatment (after surgery) with Tagrisso reduced the risk of disease recurrence or death by 83% (based on a hazard ratio [HR] of 0.17; 95% confidence interval [CI] 0.12, 0.23; p<0.0001). DFS results in the overall trial population, Stage IB through IIIA, a key secondary endpoint, demonstrated a reduction in the risk of disease recurrence or death of 79% (based on a HR of 0.21; 95% CI 0.16, 0.28; p<0.0001).